Share of U.S. physicians familiar with autoimmune biosimilars as of 2021
According to a survey conducted among U.S. rheumatologists in 2021, around 39 percent were aware that there are biosimilars to Rituxan (infliximab) that are also FDA approved but not launched yet, while around 83 percent of physicians stated that they were familiar with the FDA definition of a biosimilar product. This statistic illustrates the percentage of rheumatologists familiar with autoimmune biosimilars in the United States as of 2021.